French pharma major Sanofi (Euronext: SAN) said today that it filed a patent infringement suit against US peer Merck & Co (NYSE: MRK) on September 16, 2016 in the USA District Court for the District of Delaware. In its suit Sanofi alleges infringement of 10 patents relating to its blockbuster diabetes treatment Lantus (insulin glargine).
The suit was triggered by a notification received from Merck in early August, in which Merck stated that it had filed a New Drug Application with the US Food and Drug Administration for an insulin glargine drug product.
Merck also stated that its NDA included a paragraph IV certification challenging all of the ten Sanofi patents listed in the FDA Orange Book for Sanofi's Lantus and Lantus SoloStar products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze